STOK Stoke Therapeutics, Inc.
Healthcare$31.03+5.76%ClosedMarket Cap: $1.93B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.69
P/S
56.96
EV/EBITDA
-9.40
DCF Value
$-49.58
FCF Yield
-8.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.4%
Operating Margin
-577.5%
Net Margin
-529.2%
ROE
-48.8%
ROA
-38.3%
ROIC
-45.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.2M | 83.2% | $-53.4M | $-50.0M | $— | — |
| Q4 null | $1.4M | 24.8% | $-61.4M | $-57.9M | $— | — |
| FY null | $184.4M | 100.0% | $-20.6M | $-6.9M | $— | — |
| Q3 null | $10.6M | 90.7% | $-43.1M | $-38.3M | $— | — |
| Q2 null | $13.8M | 100.0% | $-27.3M | $-23.5M | $— | — |
| Q1 null | $158.6M | 100.0% | $111.2M | $112.9M | $— | — |
| Q4 null | $22.6M | 100.0% | $-13.7M | $-10.5M | $— | — |
| FY null | $36.6M | 100.0% | $-101.4M | $-89.0M | $— | — |
| Q3 null | $4.9M | 100.0% | $-30.0M | $-26.4M | $— | — |
| Q2 null | $4.8M | 77.0% | $-29.3M | $-25.7M | $— | — |
| Q1 null | $4.2M | 73.6% | $-28.4M | $-26.4M | $— | — |
| Q4 2023 | $2.8M | 56.6% | $-29.6M | $-27.0M | $-0.60 | — |